Paeds SAQs · growth-development-and-behaviour
Motor delay, hypotonia and the floppy infant — formative SAQs
Two formative SAQs on central versus peripheral localisation, can't-miss SMA and botulism pathways, and structured first-line work-up.
On this page & tools
Target exams
RACP General PaediatricsRACP DWEMRCPCH TheoryMRCPCH ClinicalABP General Pediatrics
Prompt
Motor delay, hypotonia and the floppy infant
SAQ 1 — Localisation and first-line safety (10 marks)
A 3-month-old is referred because she “feels floppy.” She smiles socially. Head control is poor. Limbs hang with limited antigravity movement. Deep tendon reflexes are difficult to elicit. The tongue shows fasciculations. Work of breathing is mildly increased with feeds. [1] [9]
Questions
- Localise the likely pattern (central versus peripheral) and give three bedside discriminators that support your answer. (3 marks) [1] [2]
- List the immediate safety and diagnostic actions you take today, in order of priority. (4 marks) [5] [9]
- Explain why “watch and wait for tone to improve” is unsafe here. (3 marks) [9]
Model answer
1. Localisation (3)
- Peripheral / motor-unit pattern is most likely.
- Discriminators: true weakness with antigravity failure; hyporeflexia/areflexia; tongue fasciculations (anterior horn cell clue); relative early social alertness does not exclude SMA. [1] [2] [9]
2. Immediate actions (4)
- Protect airway/feeding: assess work of breathing, cough, secretions, aspiration risk; support feeds if swallow unsafe.
- Urgent SMN1 deletion testing with SMN2 copy-number context (or confirm newborn-screen result if already done).
- Rapid neuromuscular centre referral for disease-modifying pathway consideration.
- Baseline supportive plan: physiotherapy, respiratory review, family counselling; do not delay therapy waiting for every secondary test. [5] [9]
3. Against observation alone (3)
- Infantile-onset SMA is time-critical; motor neurons are lost while observation continues.
- Disease-modifying therapy improves motor outcomes when started early (ENDEAR-class evidence for nusinersen pathways).
- Progressive areflexic weakness is never a “benign congenital hypotonia” label. [9]
Continue reading
Paediatrics Fellowship Pro
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References7Show ledgerHide ledger
- [1]Peredo DE, Hannibal MC The floppy infant: evaluation of hypotonia. Pediatrics in review, 2009.PMID 19726697
- [2]Bodensteiner JB The evaluation of the hypotonic infant. Seminars in pediatric neurology, 2008.PMID 18342256
- [5]Laverty CG Hypotonia in the Newborn Infant. Pediatric clinics of North America, 2025.PMID 40619196
- [9]Finkel RS, Mercuri E, Darras BT Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. The New England journal of medicine, 2017.PMID 29091570
- [15]Panditrao MV, Dabritz HA, Kazerouni NN Descriptive Epidemiology of Infant Botulism in California: The First 40 Years. The Journal of pediatrics, 2020.PMID 32800814
- [16]Sarintra N, Ekdahl R, Sanders SC More Than Just a Floppy Baby: Maintaining High Clinical Suspicion of Infant Botulism. Cureus, 2026.PMID 41728439
- [17]Suzui R, Wada I, Matsubara M Undiagnosed Maternal Myotonic Dystrophy Type 1 Revealed by Congenital Myotonic Dystrophy in the Neonate. Cureus, 2026.PMID 42037975